GRCE furnishes Q3 2025 results and updates corporate presentation

Rhea-AI Filing Summary

Grace Therapeutics (GRCE) furnished an 8-K noting it issued a press release with financial results for the three months ended September 30, 2025. The company also updated its corporate presentation, which includes its updated cash position as of October 31, 2025.

The press release and presentation are furnished as Exhibits 99.1 and 99.2. The company states these materials are furnished, not “filed,” under the Exchange Act.

false000144419200014441922025-11-132025-11-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 13, 2025

GRACE THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

State of Delaware	001-35776	98-1359336
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

103 Carnegie Center Suite 300
Princeton, New Jersey		08540
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: 609-322-1602

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		GRCE		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

The following information is furnished pursuant to Item 2.02 “Results of Operations and Financial Condition.”

On November 13, 2025, Grace Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such a filing or document.

Item 8.01 Other Events.

On November 13, 2025, the Company updated its corporate presentation, which includes its updated cash position as of October 31, 2025. A copy of the updated corporate presentation is attached hereto as Exhibit 99.2 to this Form 8-K and is incorporated by reference into this Item 8.01.

Item 9.01 Exhibits.

(d) Exhibits

Exhibit		Description
99.1		Press Release, dated November 13, 2025.
99.2		Corporate Presentation, dated November 13, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			GRACE THERAPEUTICS, INC.
Date:	November 13, 2025	By:	/s/ Prashant Kohli
			Prashant Kohli
			Chief Executive Officer

FAQ

What did GRCE announce in its 8-K?

The company furnished a press release with financial results for the quarter ended September 30, 2025, and an updated corporate presentation.

Which exhibits were included with GRCE’s 8-K?

Exhibit 99.1 is the press release and Exhibit 99.2 is the corporate presentation.

Does the 8-K include GRCE’s cash position?

The updated corporate presentation includes the company’s updated cash position as of October 31, 2025.

Are the materials considered filed under the Exchange Act?

No. The company states the information is furnished, not “filed,” and is not subject to Section 18 liabilities.

What period do the reported results cover for GRCE?

The results are for the three months ended September 30, 2025.